SCHEMBL4887861

SCHEMBL4887861

COc1cc(CN2C(=O)C(=Cc3ccc(-c4ccc(C(=O)O)cc4)o3)SC2=S)cc(OC)c1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.68
MEN1 O00255 2/20 0.62
ALDH1A1 P00352 2/20 0.62
POLB P06746 2/20 0.62
MAPT P10636 2/20 0.62
KMT2A Q03164 2/20 0.62
MCL1 Q07820 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
PTPN22 Q9Y2R2 2/20 0.62
PKM P14618 1/20 0.62
PTPN7 P35236 1/20 0.62
PTPN12 Q05209 1/20 0.62
EIF4E P06730 1/20 0.58
EIF4G1 Q04637 1/20 0.58
THRB P10828 1/20 0.58
RECQL P46063 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MAP3K5 Q99683 1/20 0.58
ENPP2 Q13822 2/20 0.57
APEX1 P27695 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4887856 1.00 STAT3 (0.68) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL4890217 0.92 SYK (0.57) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL4890213 0.92 SYK (0.57) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339370 0.87 MEN1 (0.77) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339369 0.87 MEN1 (0.77) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339322 0.86 STAT3 (0.67) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339319 0.86 STAT3 (0.67) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339790 0.85 STAT3 (0.69) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL20339788 0.85 STAT3 (0.69) STAT3MEN1ALDH1A1POLBMAPT
SCHEMBL4394171 0.85 STAT3 (0.66) STAT3MEN1ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed
US-20040002526-A1 Phospholipase D inhibitors and uses thereof CELL THERAPEUTICS, INC. 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002526-A1 Phospholipase D inhibitors and uses thereof PLD2, PLD1, PLA2G2D STAT3 1493/4885MEN1 3009/4885ALDH1A1 1070/4885
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN STAT3 329/4885MEN1 2216/4885ALDH1A1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.